Why Estrogen Alone Is Not Enough for Vaginal Tissue Health in Midlife

The problem isn’t simply estrogen deficiency.

It’s that tissue biology hasn’t been fully accounted for.

For decades, midlife care has centered on one idea:

If estrogen declines, replace estrogen.

This framing is tidy.
It’s also incomplete.

Estrogen is essential — but estrogen alone does not restore tissue integrity, sensation, or resilience once midlife changes begin. [1,2]

To understand why, we need to look at how estrogen actually works in the body — and what it depends on.

A Simple Way to Understand This

One way to understand this pattern is as a mismatch between signal and capacity at the tissue level.

In midlife vaginal tissue, outcomes are determined not just by hormone levels, but by the relationship between:

• Hormonal signaling (estrogen, ex)
• Available substrate (DHEA → testosterone)
• Tissue response capacity (vascular, neural, metabolic function)

When these fall out of alignment, symptoms can persist or be partially alleviated, even when estrogen is present.

The easiest way to understand this is to look at how signal, substrate, and tissue response interact at the local level:

Figure: Tissue Response Model of Midlife Vaginal Health (Dr. Laura Kelly)

This model reflects a systems-based view of vaginal tissue function in midlife, integrating hormonal signaling, substrate availability, and tissue response.

Signal refers to the hormonal messages that bind to receptors and initiate cellular activity within vulvovaginal tissue. This includes estrogen as well as androgens such as testosterone. These signals provide instruction to the tissue, but do not by themselves ensure that a functional response will occur.  IIn midlife, many of these signals are reduced or altered.

Material or Substrate (DHEA) is the raw biological input required for local hormone production. DHEA serves as the precursor from which tissues generate both estrogens and androgens according to local need.  In midlife when circulating hormones are gone, this pathway still works, it just needs DHEA, the precursor.  

Local Conversion (Intracrine Function) describes the process by which enzymes within the tissue convert DHEA into active hormones such as testosterone and estradiol directly at the site of action. This allows the tissue to regulate its own hormonal environment independently of circulating levels.

Tissue Response Capacity reflects the ability of the tissue to respond to hormonal signaling. This capacity is determined by vascular function, including nitric oxide–mediated blood flow, neural signaling and sensory responsiveness, structural integrity such as epithelial thickness and collagen organization, and metabolic capacity including cellular energy production and repair.

Outcome is the clinical expression of these combined processes, including comfort, lubrication, arousal, sensation, and overall tissue resilience. When signaling, substrate availability, and tissue capacity are aligned, function is restored. When they are not, symptoms may persist even in the presence of adequate hormone levels.

Why Current Approaches Often Fall Short

Most treatments address only one layer of the system:

• Estrogen therapy
  → improves epithelial integrity
  → does not restore androgen-dependent signaling
• Lubricants
  → reduce friction
  → do not change tissue biology
• Systemic hormone approaches
  → provide circulating hormones
  → do not ensure local tissue conversion or response

Because these approaches do not address substrate availability and tissue capacity simultaneously, outcomes are often partial.

Estrogen Improves Tissue Integrity — But Androgens Drive Sexual Response

Estrogen plays a critical role in maintaining genital tissue integrity.
It supports epithelial thickness, glycogen availability, collagen organization, and baseline resilience of vulvovaginal tissue. [1,2]

But genital tissues are not estrogen-only tissues.

They are also androgen-responsive tissues (testosterone), and androgen receptor signaling governs biological processes that estrogen does not reliably restore [3,4] — particularly those related to sexual desire, arousal physiology, and sensory responsiveness. [3,5]

Estrogen can stabilize tissue.
It cannot, on its own, reproduce the full androgen-dependent biology required for a complete sexual response.

For estrogen to translate into comfort and responsiveness, the body must also have:

• Adequate local androgen signaling
  (via testosterone, which is DHEA-derived substrate)

• Functional intracrine enzyme activity
  (allowing tissue to generate the balance of hormones it requires locally)

• Intact nitric oxide and vascular response pathways
  (necessary for genital blood flow and arousal)

• Healthy peripheral nerve signaling
  (critical for sensation and feedback to central desire circuits)

When androgen signaling is insufficient — which commonly occurs in midlife — estrogen may reduce dryness or fragility, yet desire and arousal remain blunted.[5]

This is not a failure of estrogen.
It is a reflection of incomplete hormonal signaling at the tissue level.

Why Estrogen Alone Often Improves Comfort but Not Desire

Estrogen primarily supports structural and maintenance functions within genital tissue.
Desire and arousal, however, depend on androgen-mediated vascular, neural, and signaling pathways that estrogen cannot fully replace.

This is why many women report:

• reduced irritation or dryness

• improved tissue comfort
  —but still experience muted sexual response or loss of desire

The Role of Testosterone and DHEA in Genital Tissue Function

DHEA, and the testosterone derived from it within the cell, act as essential substrates for androgen receptor signaling in genital tissue. [4,6]
Their presence supports:

• nitric oxide–mediated vasocongestion

• sensory nerve responsiveness

• tissue-level feedback that contributes to sexual motivation and pleasure

Without sufficient androgen availability, estrogen signaling remains partial.

• Desire is partly central (brain) and partly peripheral (genital response feedback loop). Testosterone (created from DHEA) affects both.

• Local DHEA can support local androgen/estrogen balance via intracrine conversion, but it’s still substrate-dependent and varies by tissue enzyme expression.

So: estrogen-only care can be necessary but insufficient for many women.

The Intracrine Reality Most Care Ignores in Vaginal and Vulvar Tissue

Genital tissues are not passive recipients of circulating hormones.
They are active endocrine environments that rely on local hormone production to regulate function. [7,8]

Much of the estrogen and androgen activity within vulvovaginal tissue is generated inside the tissue itself through intracrine metabolism, using DHEA as the primary substrate.

This local process matters because tissue-level needs simply cannot be met by circulating estrogen alone.

Local Hormone Production Happens Inside the Vaginal and Vulvar Tissue

Vaginal and vulvar tissues express the enzymatic machinery required to convert DHEA into both estrogens and androgens locally, [7,8] according to tissue-specific demand. This is a primary mechanism through which healthy vulvovaginal tissue maintains function.

This allows the tissue to:

• fine-tune hormone balance independent of systemic levels

• respond to mechanical, neural, and vascular signals in real time

• support both epithelial integrity and androgen-mediated responsiveness

When intracrine capacity is intact and receive DHEA, tissues can maintain flexibility and function even as systemic hormone levels decline.

Why DHEA Is the Limiting Substrate

DHEA is not just another hormone.
It is the raw material from which tissues generate what they need locally. [6,9]

Estrogen cannot substitute for this role.

Once estrogen is formed, it cannot convert back into testosterone or DHEA. [7]
If DHEA substrate is absent, estrogen signaling remains partial — no matter how much estrogen is present.

This is why estrogen-only approaches can stabilize tissue condition but fail to restore full sexual response.

Why Systemic Estrogen Cannot Replace Local Substrate

Systemic estrogen delivers a signal, not a substrate.

It can activate estrogen receptors, but it cannot:

• supply androgen precursors

• rebuild androgen receptor–dependent pathways

• restore nitric oxide–mediated arousal signaling

• support sensory nerve responsiveness driven by androgen signaling [3,4]

In tissues where androgen activity is required such as the vulva and vagina, estrogen alone cannot complete the job.

Signal vs Material: The Missing Distinction

Estrogen functions as a signal.
DHEA functions as material.

Signals instruct tissues what to do.
Materials determine whether they can do it. [6,7]

When the material is missing, signaling becomes fragile.

This distinction explains why:

• labs may appear “normal”

• estrogen therapy may partially help

• but comfort, responsiveness, and desire do not fully return

The issue is not hormone presence.
It is substrate availability and tissue capacity.

This breakdown is most clearly expressed clinically as Genitourinary Syndrome of Menopause (GSM), a diagnosis that captures symptoms, but not the full biology driving them. [12]

Why Estrogen Therapy Can Plateau Over Time

Many women experience an initial improvement after starting estrogen therapy — followed by a stall. [5,10]

Early benefits often reflect estrogen’s ability to improve epithelial integrity, hydration, and baseline tissue resilience. These changes can reduce irritation, dryness, and fragility, particularly in the first months of use.

Over time, however, progress may level off.

This plateau occurs because estrogen does not correct several age-related, tissue-level limitations that become more prominent in midlife, including:

• declining androgen availability within genital tissue

• reduced intracrine conversion capacity

• diminished mitochondrial energy production

• impaired vascular responsiveness and nitric oxide signaling

• changes in sensory nerve function [4,5,11]

When these factors limit tissue responsiveness, estrogen signaling continues — but its effects remain partial.

This is why symptoms may improve initially, yet desire, arousal, and full tissue responsiveness do not fully return.

The plateau is not a failure of treatment.
It reflects biological limits that estrogen alone cannot overcome.

Why Increasing Estrogen Dose Isn’t the Answer

When progress stalls, it is common to assume that estrogen levels are still too low.

But in many cases, the limiting factor is not estrogen availability. [12]

Increasing estrogen dose can further stimulate estrogen receptors, but it does not:

• restore local androgen signaling [3,4]

• replenish DHEA or testosterone substrate [5,6]

• rebuild androgen receptor–dependent pathways [3,4]

• correct vascular or nitric oxide deficits [3]

• repair age-related changes in cellular energy capacity [7,8]

As a result, dose escalation may increase exposure without meaningfully improving function. [1,2]

In some cases, higher doses can also introduce unwanted effects — not because estrogen is harmful, but because it is being asked to perform roles outside its biological scope. [1]

When estrogen is no longer the rate-limiting factor, more estrogen does not produce more response.

At that point, the issue is not hormone deficiency, it is tissue capacity and signaling balance.  [5,7]

Understanding this more complex biology reframes midlife care.
The question is no longer whether estrogen is present — but whether tissues have everything they need to respond as you want them to. 

Educational Note

This content is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any medical condition.

Cited Scientific Sources:

1. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology. Menopause. 2014;21(10):1063–1068.
2. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause. Menopause. 2020;27(9):976–992.
3. Davis SR, Baber R, Panay N, et al. Global consensus position statement on testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
4. Traish AM, Goldstein I, Kim NN. Testosterone and genital tissue function in women and men. Endocr Rev. 2007;28(4):413–444.
5. Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions. Sex Med Rev. 2021;9(1):1–18.
6. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal DHEA on moderate to severe dyspareunia. Menopause. 2009;16(5):907–922.
7. Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78(3):C113–C118.
8. Martel C, Labrie F. Intracrine metabolism of sex steroids. J Steroid Biochem Mol Biol. 2003;85(2–5):459–465.
9. Stárka L, Dušková M, Hill M. Dehydroepiandrosterone: a neuroactive steroid. J Steroid Biochem Mol Biol. 2015;145:254–260.
10. Islam RM, Bell RJ, Green S, et al. Safety and efficacy of intravaginal DHEA in postmenopausal women: systematic review. Menopause. 2022.
11. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder. Mayo Clin Proc. 2017;92(1):114–128.
12. López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194–1217.
13. Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest. 2013;123(3):951–957.

By Dr. Laura Kelly, DAOM
Doctor of Acupuncture and Oriental Medicine. Researcher in systems biology and midlife physiology. Developer of the Tissue Response Model of Vaginal Health.
Learn more about Dr. Kelly